Tachykinin NK2 antagonist for treatments of various disease states


      Tachykinin NK2 receptors are distributed in periphery, in the smooth muscle of the respiratory, gastrointestinal, genitourinary tract, and within the brain. Substance P (SP), neurokinin A (NKA), and neurokinin B (NKB) are endogenous ligands for NK2 receptors and are active in the peripheral and central nervous systems. NK2 antagonists have the potential to reduce airway motor responses and prevent hyperactivity by inhibiting NKA-induced bronchoconstriction in asthmatic patients. Due to its abundance, peripherally and centrally, tachykinin NK2 receptor antagonists have high potential in treating various disease states ranging from asthma to irritable bowel syndrome, to detrusor hyperactivity, to anxiety. This review is an evaluation of NK2 receptor antagonists as possible therapeutics for a myriad of pharmacological treatments.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Autonomic Neuroscience: Basic and Clinical
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Advenier C.
        • Naline E.
        • Toty L.
        • et al.
        Effects on the isolated human bronchus of SR 48968, a potent and selective nonpeptide antagonist of the neurokinin a (NK2) receptors.
        Am. Rev. Respir. Dis. 1992; 146: 1177-1181
        • Advenier C.
        • Lagente V.
        • Boichot E.
        The role of tachykinin receptor antagonists in the prevention of bronchial hyperresponsiveness, airway inflammation and cough.
        Eur. Respir. J. 1997; 10: 1892-1906
        • Altamura M.
        Tachykinin NK2 receptor antagonists. A patent review (2006 – 2010).
        Expert Opin. Ther. Pat. 2011; 22: 57-77
        • Barnes P.J.
        Airway neuropeptides and asthma.
        Trends Pharmacol. Sci. 1987; 8: 24-27
        • Birder L.A.
        • de Groat W.C.
        Induction of c-fos expression in spinal neurons by nociceptive and nonnociceptive stimulation of LUT.
        Am. J. Phys. 1993; 265: R326-R333
        • Buckner C.K.
        • Dna D.
        • Lmzn
        • Ti N.
        A pharmacologic examination of receptors mediating serotonin-induced bronchoconstriction in the anesthetized guinea pig.
        J. Pharmacol. Exp. Ther. 1991; 257: 26-34
        • Buckner C.K.
        • Liberati N.
        • Dea D.
        • et al.
        Differential blockade by tachykinin NK1 and NK2 receptor antagonists of bronchoconstriction induced by direct-acting agonists and the indirect-acting mimetics capsaicin, serotonin and 2-methyl-serotonin in the anesthetized Guinea pig.
        J. Pharmacol. Exp. Ther. 1993; 267: 1168-1175
        • Cheng C.L.
        • Liu J.C.
        • Chang S.Y.
        • et al.
        Effect of capsaicin on the micturition reflex in normal and chronic spinal cord-injured cats.
        Am. J. Phys. 1999; 277: R786-R794
        • Choppin A.
        • Groke G.
        • Bringas A.
        • et al.
        Effect of YM-44781, YM-44778 and YM-49598, novel tachykinin antagonists, in a drug-induced bladder contraction model.
        Pharmacology. 2002; 65: 96-102
        • Cialdai C.
        • Tramontana M.
        • Patacchini R.
        • et al.
        MEN 15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
        Eur. J. Pharmacol. 2006; 549: 140-148
        • Corboz M.R.
        • Fernandez X.
        • Hey J.A.
        Increased blocking activity of combined tachykinin NK1- and NK2-receptor antagonists on hyperventilation-induced bronchoconstriction in the Guinea pig.
        Pulm. Pharmacol. Ther. 2008; 21: 67-72
        • Corsetti M.
        • Akyuz F.
        • Tack J.
        Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome.
        Neurogastroenterol. Motil. 2015; 27: 1354-1370
        • Costall B.
        • Domeney A.M.
        • Gerrard P.A.
        • et al.
        Zacopride: anxiolytic profile in rodent and primate models of anxiety.
        J. Pharm. Pharmacol. 1988; 40: 302-305
        • Costall B.
        • Jones B.J.
        • Kelly M.E.
        • et al.
        Exploration of mice in a black and white test box:validation as a model of anxiety.
        Pharmacol. Biochem. Behav. 1989; 32: 777-785
        • Desvignes C.
        • Rouquier L.
        • Souilhac J.
        • et al.
        Control by tachykinin NK2 receptors of CRF1 receptor-mediated activation of hippocampal acetylcholine release in the rat and Guinea-pig.
        Neuropeptides. 2003; 37: 89-97
        • Dong W.Z.
        • Zou D.W.
        • Li Z.S.
        • et al.
        Study of visceral hypersensitivity in irritable bowel syndrome.
        Chin. J. Dig. Dis. 2004; 5: 103-109
        • Drimousis S.
        • Markus I.
        • Murphy T.V.
        • et al.
        Gender-related differences of tachykinin NK2 receptor expression and activity in human colonic smooth muscle.
        J. Pharmacol. Exp. Ther. 2020; 375: 28-39
        • Endo Y.
        • Shoji T.
        • Fukudo S.
        Epidemiology of irritable bowel syndrome.
        Ann. Gastroenterol. 2015; 28: 158-159
        • Giuliani S.
        • Maggi C.A.
        • Rovero P.
        • et al.
        Neurokinins induce a relaxation of rat duodenum in vivo by activating postganglionic sympathetic elements in prevertebral ganglia: involvement of an NK2 type of neurokinin receptors.
        J. Pharmacol. Exp. Ther. 1988; 246: 322-327
        • Hagan R.M.
        • Beresford I.J.M.
        • Stables J.S.
        • et al.
        Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists.
        Regul. Pept. 1993; 46: 9-19
        • Hall J.M.
        • Flowers J.M.
        • Morton I.K.M.
        • et al.
        A pharmacological study of NK1 and NK2 tachykinin receptor characteristics in the rat isolated urinary bladder.
        Br. J. Pharmacol. 1992; 107: 777-784
        • Hallgren A.
        • Flemstrom G.
        • Hellstrom P.M.
        • et al.
        Neurokinin a increases duodenal mucosal permeability, bicarbonate secretion and fluid output in the rat.
        Am. J. Phys. 1997; 273: G1077-G1086
        • Hey J.A.
        • Danko G.
        • del Prado M.
        • et al.
        Augmentation of neurally evoked cholinergic bronchoconstrictor responses by prejunctional NK2 receptors in the Guinea-pig.
        J. Auton. Pharmacol. 1996; 16: 41-48
        • Johansson O.
        • Hökfelt T.
        • Pernow B.
        • et al.
        Immunohistochemical support for three putative transmitters in one neuron: coexistence of 5-hydroxytryptamine, substance p- and thyrotropin releasing hormone-like immunoreactivity in medullary neurons projecting to the spinal cord.
        Neuroscience. 1981; 6: 1857-1881
        • Joos G.F.
        • Germonpre P.R.
        • Pauwels R.A.
        Role of tachykinins in asthma.
        Allergy. 2000; 55: 321-337
        • Joos G.F.
        • Vincken W.
        • Louis R.
        • et al.
        Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients.
        Eur. Respir. J. 2004; 23: 76-81
        • Julia V.
        • Morteau O.
        • Bueno L.
        Involvement of neurokinin 1 and 2 receptors in viscerosensitive response to rectal distension in rats.
        Gastroenterology. 1994; 107: 94-102
        • Kiss S.
        • Yoshiyama M.
        • Cao Y.Q.
        • et al.
        Impaired response to chemical irritation of the urinary tract in mice with disruption of the preprotachykinin gene.
        Neurosci. Lett. 2001; 313: 57-60
        • Kojima S.
        • Ueda S.
        • Ikeda M.
        • et al.
        Calcitonin gene-related peptide facilitates serotonin release from Guinea-pig colonic mucosa via myenteric neurons and tachykinin NK2/NK3 receptors.
        Br. J. Pharmacol. 2004; 141: 385-390
        • Kuo H.C.
        Effects of capsaicin on detrusor contractility of rats: an in vivo and isolated whole bladder study.
        Urol. Int. 1996; 57: 51-57
        • Lecci A.
        • Giuliani S.
        • Garret C.
        • et al.
        Evidence for a role of tachykinins as sensory transmitters in the activation of micturition reflex.
        Neuroscience. 1993; 54: 827-837
        • Lecci A.
        • Valenti C.
        • Maggi C.A.
        Tachykinin receptor antagonists in irritable bowel syndrome.
        Curr. Opin. Ivestig. Drugs. 2002; 3: 589-601
        • Lecci A.
        • Capriati A.
        • Maggi C.A.
        Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome.
        Br. J. Pharmacol. 2004; 141: 1249-1263
        • Lou Y.-P.
        • Delay-Goyet P.
        • Lundberg J.M.
        Selective inhibition by dactinomycin of NANC sensory bronchoconstriction and [125I] NKA binding due to NK-2 receptor antagonism.
        Acta Physiol. Scand. 1992; 144: 221-231
        • Maggi C.A.
        Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released from peripheral endings of sensory nerves.
        Prog. Neurobiol. 1995; 45: 1-98
        • Maggi C.A.
        • Patacchini R.
        • Rovero P.
        • et al.
        Tachykinin receptors and tachykinin receptor antagonists.
        J. Auton. Pharmacol. 1993; 13: 23-93
        • Maggi C.A.
        • Patacchini R.
        • Bartho L.
        • et al.
        Tachykinin NK1 and NK2 receptor antagonists and atropine-resistant ascending excitatory reflex to the circular muscle of the Guinea-pig ileum.
        Br. J. Pharmacol. 1994; 112: 161-168
        • Maggi C.A.
        • Giachetti A.
        • Dey R.D.
        • et al.
        Neuropeptides as regulators of airway function: vasoactive intestinal peptide and the tachykinins.
        Physiol. Rev. 1995; 75: 277-322
        • Nakamura A.
        • Tanaka T.
        • Imanishi A.
        • et al.
        Bidirectional regulation of human colonic smooth muscle contractility by tachykinin NK2 receptors.
        J. Pharmacol. Sci. 2011; 117: 106-615
        • Onori L.
        • Aggio A.
        • Taddei G.
        • et al.
        Contribution of NK2 tachykinin receptors to propulsion in the rabbit distal colon.
        Am. J. Phys. 2000; 278: G137-G147
        • Patacchini R.
        • Astolfi M.
        • Quartara L.
        • et al.
        Further evidence for the existence of NK2 tachykinin receptor subtypes.
        Br. J. Pharmacol. 1991; 104: 91-96
        • Quartara L.
        • Pavone V.
        • Pedone C.
        • et al.
        A review of the design, synthesis and biological activity of the bicyclic hexapeptide tachykinin NK2 antagonist MEN 10627.
        Regul. Pept. 1996; 65: 55-59
        • Rawla P.
        • Sunkara T.
        • Raj J.P.
        Updated review of current pharmacological and non-pharmacological management of irritable bowel syndrome.
        Life Sci. 2018; 212: 176-181
        • Ray D.W.
        • Hernandez C.
        • Leff A.R.
        • Drazen J.M.
        • Solway J.
        Tachykinins mediate bronchoconstriction elicited by isocapnic hyperpnea in guinea pigs.
        Journal of Applied Physiology. 1989; 66: 1108-1112
        • Renzi D.
        • Pellegrini B.
        • Tonelli F.
        • et al.
        Substance P (neurokinin-1) and neurokinin a (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine.
        Am. J. Pathol. 2000; 157: 1511-1522
        • Rey E.
        • Talley N.J.
        Irritable bowel syndrome: novel views on the epidemiology and potential risk factors.
        Dig. Liver Dis. 2009; 41: 772-780
        • Ribeiro R.L.
        • De Lima T.C.M.
        Participation of GABAA receptors in the modulation of experimental anxiety by tachykinin agonists and antagonists in mice.
        Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2002; 26: 861-869
        • Rogacki N.
        • Lopez-Grancha M.
        • Naimoli V.
        • et al.
        The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition.
        Pharmacol. Biochem. Behav. 2011; 98: 405-411
        • Rosen A.
        • Franck J.
        • Brodin E.
        Effects of acute systemic treatment with the 5-HT-uptake blocker alaproclate on tissue levels and release of substance P in rat periaqueductal grey.
        Neuropeptides. 1995; 28: 317-324
        • Saito Y.A.
        • Talley N.J.
        Genetics of irritable bowel syndrome.
        Am. J. Gastroenterol. 2008; 103: 2100-2105
        • Sculptoreanu A.
        • De Groat W.C.
        Protein kinase C is involved in neurokinin receptor modulation of N- and L-type Ca2 channels in dorsal root ganglia neurons of the adult rat.
        J. Neurophysiol. 2003; 90: 21-31
        • Solway J.
        • Kao B.M.
        • Jordan J.E.
        • et al.
        Tachykinin receptor antagonists inhibit hyperpnea-induced bronchoconstriction in Guinea pigs.
        J. Clin. Invest. 1993; 92: 315-323
        • Stratton S.C.
        • Beresford I.J.M.
        • Elliott P.J.
        Behavioural effects of centrally infused tachykinin NK2 receptor agonists and antagonists in rat models of anxiety.
        J. Psychophannacol. 1993; 7
        • Stratton S.C.
        • Beresford I.J.M.
        • Harvey F.J.
        Anxiolytic activity of tachykinin NK2 receptor antagonists in the mouse light-dark box.
        Eur. J. Pharmacol. 1993; 250Rll-R12
        • Stratton S.C.
        • Beresford I.J.M.
        • Hagan R.M.
        GR 159897, a potent non-peptide tachykinin NK2 receptor antagonist, release supressed behaviors in a novel aversive environment.
        Br. J. Pharmacol. 1994; 112: 49
        • Szymaszkiewicz A.
        • Malkiewicz A.
        • Storr M.
        • et al.
        The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome.
        J. Physiol. Pharmacol. 2019; 70
        • Walsh D.M.
        • Stratton S.C.
        • Harvey F.J.
        • et al.
        The anxiolytic-like activity of GR 159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety.
        Psychopharmacology. 1995; 121: 186-191
        • Wang H.F.
        • Shortland P.
        • Park M.J.
        • et al.
        Retrograde and transganglionic transport of horseradish peroxidase-conjugated cholera toxin B subunit, wheatgerm agglutinin and isolectin B4 from griffonia simplicifolia I in primary afferent neurons innervating the rat urinary bladder.
        Neuroscience. 1998; 87: 288
        • Wang L.-H.
        • Fang X.-C.
        • Pan G.-Z.
        Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis.
        Gut. 2004; 53: 1096-1101
        • Warner F.J.
        • Liu L.
        • Lubowski D.Z.
        • et al.
        Circular muscle contraction, messenger signalling and localization of binding sites for neurokinin a in human sigmoid colon.
        Clin. Exp. Pharmacol. Physiol. 2000; 27: 928-933
        • Zeng X.P.
        • Moore K.H.
        • Burcher E.
        Characterization of tachykinin NK2 receptors in human urinary bladder.
        J. Urol. 1995; 153: 1688-1692